argenx SE — FY2022 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under IFRS as issued by the IASB and presented in U.S. dollars.
Business context
argenx is a commercial-stage biopharmaceutical company focused on severe autoimmune diseases. VYVGART (efgartigimod) for generalized myasthenia gravis (gMG) was its only approved product. It was approved in the U.S. in December 2021, Japan in January 2022, and the EU in August 2022; launches began in the U.S., Japan, and Germany during 2022. The company is developing efgartigimod in additional indications and advancing other pipeline candidates, including ARGX-117 and ARGX-119.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Product net sales | $400.7 million | None |
| Collaboration revenue | $10.0 million | $497.3 million |
| Total operating income | $445.3 million | $539.4 million |
| Research and development expense | $663.4 million | $580.5 million |
| Selling, general and administrative expense | $472.1 million | $307.6 million |
| Operating loss | $720.3 million | $348.7 million |
| Net loss | $709.6 million | $408.3 million |
| Comprehensive loss | $730.3 million | $450.6 million |
| Basic and diluted loss per share | $13.05 | $7.99 |
| Net cash used in operating activities | $862.8 million | $606.8 million |
VYVGART gross sales were $446.9 million; gross-to-net deductions were $46.2 million. Cost of sales was $29.4 million. No operating margin guidance or clear standalone Q4 financial results are provided in the filing text.
At December 31, 2022, cash and cash equivalents were $800.7 million and current financial assets were $1,391.8 million, totaling $2,192.5 million, versus $2,336.7 million a year earlier. Current assets were $2,774.2 million and current liabilities $302.3 million. Total assets were $3,134.3 million; total equity was $2,813.7 million. The company reported no financial debt; lease liabilities totaled $12.4 million, including $3.4 million current. No cash dividends were declared, other than nominal distributions connected with vested RSUs.
Cash flows included $461.2 million used in investing activities and $843.8 million provided by financing activities, primarily from the 2022 share offering and option exercises. The filing reports approximately $761 million net cash proceeds from the 2022 offering. Capital expenditures were $108.2 million, including the PRV and other intangible-asset purchases.
Material changes versus FY2021
- argenx generated its first product sales, with $400.7 million of VYVGART net sales; U.S. sales were $377.7 million.
- Collaboration revenue fell by $487.3 million, mainly because substantial upfront and termination-related revenue recognized from Zai Lab and Janssen in 2021 did not recur.
- Net loss widened by $301.3 million. Operating expenses rose 31%, including higher R&D and a 53% increase in SG&A as commercialization expanded.
- R&D expense included $99.1 million of amortization and derecognition of a priority review voucher used for the subcutaneous efgartigimod application.
- Operating cash use increased by $256.0 million, reflecting development, commercialization, inventory, and working-capital needs. The company raised equity capital to support operations.
Outlook, commentary, risks, and unusual items
- Management expected continued operating losses and near-term cash burn while expanding VYVGART commercialization and developing its pipeline. It stated existing cash and current financial assets were expected to fund operating expenses and capital expenditures for at least the next 12 months.
- The filing describes expected 2023 regulatory and launch milestones, including a June 20, 2023 FDA action date for subcutaneous efgartigimod in gMG, and anticipated additional geographic launches and approvals. The referenced 2023 outlook table is not present in the supplied filing text; numerical guidance is therefore unclear.
- Pipeline timelines included expected 2023 topline results for CIDP and ITP subcutaneous studies, and for pemphigus vulgaris/foliaceus in the second half of 2023; geopolitical disruption in Ukraine and Russia had increased enrollment targets and delayed the pemphigus results.
- Principal risks include clinical-trial failure or delay, adverse events, regulatory and reimbursement uncertainty, pricing pressure, competition from other FcRn inhibitors and biosimilars, dependence on third-party manufacturers and suppliers, and the possibility of needing additional capital. Some raw materials have single-source supply risks.
- Financial exposures include foreign-exchange risk, especially USD/EUR; the company had no currency hedging arrangements. A 10% EUR/USD movement was estimated to affect results by approximately $61.4 million at year-end 2022. Interest-rate sensitivity of 25 basis points was estimated at $6.2 million.
- Manufacturing commitments included $419.0 million under a Lonza commercial supply agreement and $13.3 million with Fujifilm; the company also disclosed a $13 million commitment to fund OncoVerity. These are material alongside ongoing cash burn.
- The independent auditor gave an unqualified opinion on the IFRS financial statements and internal controls. The critical audit matter was estimation of U.S. VYVGART gross-to-net deductions, which rely partly on delayed third-party reporting data.
Important facts for investors to verify
- VYVGART sales growth, payer access, gross-to-net deductions, customer concentration, and the sustainability of U.S.-weighted revenue.
- Current cash, financial-asset composition, cash burn, and the timing and size of manufacturing and other contractual commitments.
- Regulatory outcomes and trial results for subcutaneous efgartigimod and the other lead indications; confirm updated timelines against subsequent company disclosures.
- Whether 2023 outlook figures are available in the full filing or later disclosures, since the supplied text does not show a clear numerical outlook.
- Potential dilution from equity issuance and share-based compensation; 55,395,856 ordinary shares were outstanding at year-end 2022.